Nice transmission last Friday to 🇺🇸 using the excellent MEDINBOX AIR portable system !! Great case with a lot of discussion on small annulus anatomies. Gui Attizzani Abdelkader Almanfi, MD, FACC, FSCAI Medinbox thomas modine Didier Tchetche Matias Sztejfman Juan Gaspar Nicolas Gausserand

Moderating 4 Live TAVR Evolut cases from Australia 🇦🇺, Taiwan 🇹🇼, Brazil 🇧🇷 & Argentina 🇦🇷 was a great fun alongside Antonious Attallah, MD, FACC, FSCAI In-person discussions & debates about #TAVR latest data & best practices among implanters from different 12 nations (aside from US) Thanks to

What A Milestone for both of us! August 21st 2024, I proctored my mentor Dr. Strickman (who taught me TAVR 10 years ago as a fellow at THI), he performed his first Evolut FX plus TAVR case, I am so glad I was able to help, I still look up to him and learn from his wisdom, courage

Looking forward to exciting discussions on complex #TAVI cases and a lot of learning! ⁦University Hospitals⁩ ⁦Medtronic Structural Heart⁩ ⁦Vinicius Esteves,MD PhD FESC⁩ ⁦Anene Ukaigwe⁩ ⁦UH Harrington Heart & Vascular Institute⁩ ⁦Mehdi Shishehbor, DO⁩ ⁦Sandeep M Patel, M.D.⁩ ⁦Marco Frazzetto⁩ linkedin.com/posts/guilherm…

Nice discussion about coronary cannulation post-#TAVR with my brother Yohei Turi Ohno and Prof Hyo-Soo Kim starting #ENCORE Congress in Seoul. Great to meet our friend Davide Capodanno for dinner remembering our fellowship days in Italy Marco Frazzetto

Dr Shariq Shamim Read our CANNULATE TAVR study on JACC Intv on consecutive (no selection for easier anatomies) patients for 100% coronary cannulation post TAVR with FX. You can also attend our late breaking trial presentation at London Valves for the CANNULATE TAVR EXTENDED and simultaneous paper

Packed best global research in TAVR session during the very first hour of #TCT2024. Great discussion on coronary re-access and looking forward to CANULATE TRIAL to be presented during #PCRLV24 Gui Attizzani Yohei Turi Ohno Anene Ukaigwe Mehdi Shishehbor, DO UH Harrington Heart & Vascular Institute

Great sessions at Cardiovascular Research Foundation #TCT2024

Just presented 1y full TRILUMINATR RCT #T-TEER TriClip system for severe TR. ⬆️WINs, KCCQ 6MWD. Congrats to all co authors and now published in JACC Journals RTHahnMD Paul Nadira Hamid Abbott Cardiovascular #TCT2024 Cardiovascular Research Foundation TCTMD

Great Canadian #TAVI implanters meeting last weekend in Montreal. Outstanding atmosphere led by my friends Nico Piazza and Sam Radhakrishnan…and Dr. Eric Horlick showed not only his superb cardiology knowledge but also that nobody knows submarine movies like him😉 Rodrigo Bagur 🇦🇷🇨🇦

Thank you my friend ⁦Steven Yakubov⁩ for this nice podcast in which we talk about life, career, hard work and coronary access post #TAVR open.spotify.com/episode/5Xlwu6…

Congrats to Howard Herrmann, Dr Roxana Mehran Didier Tchetche and #SMART trial investigators for outstanding 2y data and outcomes #CRT2025, with excellent clinical and echo follow up! While no differences in hard endpoints (no surprise), what struck me the most is the adjudicated

ICYMI: 5-yr valve performance is significantly better after CoreValve/Evolut #TAVI compared to surgery. The development of BVD in TAVI and surgery patients was associated with worsened 5-yr clinical outcomes. jacc.org/doi/10.1016/j.… #CRT2025 #JACC #cvSurg Aakriti Gupta, MD MSc Michael Reardon

Chronic Total Occlusion PCI in diabetes at CRT Meeting

Dr. Michael Reardon on the EVOLUT Low Risk trial: 📌 Low surgical risk patients with severe AS who were treated with either Evolut or surgery showed comparable rates of all-cause mortality or disabling #stroke at 5 years (15.5% Evolut and 16.4% surgery, p=0.47) #ACC25 #JACC #SAVR

#ACC25 #Evolut low rish : low surgical risk pts with severe AS —> Evolut vs surgery —> comparable rates of all-cause mortality or disabling stroke at 5 years (15.5% Evolut and 16.4% surgery, p=0.47) The Mod Pharmacist Kimberly Imoh Rosy Thachil, MD, MBA Prasanti Alekhya Kotta, MB BChir Ugochukwu Ebubechukwu, MD 🫀 Ibrahim Kamel

Dr. Michael Reardon on the EVOLUT Low Risk trial: The results of the trial at 5 years support Evolut as a safe, effective, and durable alternative to surgery for patients with severe aortic stenosis and low surgical risk #ACC25 #TAVR #SAVR #vhdAS #cvSurg #JACC

And here are finally the 5-year results of Evolut Low Risk, a trial in which the self-expanding prosthesis holds its own against surgery. A trial where, let’s remember, the average age was 74 years. For years, to the question: 'How long does a TAVI prosthesis last?' we didn’t

This #JACCINT analysis assessed midframe underexpansion after #TAVR with the self-expanding ACURATE neo2 valve and found it occurred in 13.9% of patients. Midframe underexpansion was associated with higher 1-year mortality, stroke, and rehospitalization. jacc.org/doi/10.1016/j.…

The European Valve Durability TAVI Registry highlights the long-term performance of TAVI. The incidence of moderate or severe structural valve deterioration (SVD) during long-term follow-up was relatively low, with severe SVD being even rarer than moderate SVD. SVD occurred more